Welcome to the Department of Health Care Services Welcome to Medi-Cal Welcome to the Department of Health Care Services

Medi-Cal Logo
Click to Sign Up for MCSS emails

Updates to Physician-Administered Drugs and List of Contract Drugs

July 2, 2019

Effective for dates of service on or after April 25, 2019, BALVERSA (erdafitinib) tablets are reimbursable and subject to the following Code I restrictions: Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 59676 (Janssen Products, LP.) only.

Effective for dates of service on or after July 1, 2019, QVAR RediHaler 10.6 grams (beclomethasone dipropionate HFA) is on the Medi-Cal Contract Drugs List with a restriction to NDC labeler code 59310 (Teva Respiratory, LLC) only.

Effective for dates of service on or after July 1, 2019, acamprosate calcium tablets are reimbursable.

Effective for dates of service on or after July 1, 2019, a Treatment Authorization Request (TAR) is no longer required for reimbursement of SUBLOCADE (buprenorphine extended-release injectable solution) and VIVITROL (naltrexone for extended-release injectable suspension).

Updated manual pages will be released in a future Medi-Cal Update.